Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic reports significant three-year outcomes from the Global SYMPLICITY Registry, demonstrating that renal denervation (RDN) with the Symplicity™ System leads to substantial and lasting reductions in blood pressure (BP) for hypertensive patients. Office systolic BP decreased by 17 mmHg, with two-thirds of patients initially over 180 mmHg achieving lower BP levels. These results, achieved while patients remained on an average of four anti-hypertensive medications, underscore RDN's efficacy and safety, with a renal artery stenosis incidence of only 0.3%.
Medtronic announces FDA approval for the Percept™ PC Deep Brain Stimulation (DBS) system, incorporating BrainSense™ technology. This innovation allows for chronic capture of brain signals while delivering therapy for conditions like Parkinson's disease and OCD. The device, first implanted at Mayo Clinic, enables personalized treatment through data-driven insights. Key features include MRI compatibility, smart battery, improved longevity, and enhanced patient programming. Medtronic aims to transform care standards with this groundbreaking technology.
Medtronic announces the CE mark approval for its Evolut TAVI system to treat severe aortic stenosis in low-risk patients, now including those with bicuspid aortic valves. This new indication allows treatment for patients at extreme, high, and intermediate risks of surgical mortality. The Evolut Low Risk Trial showed TAVI's safer profile and effective outcomes, with shorter hospital stays and improved quality-of-life scores. With over 500,000 annual cases of severe aortic stenosis in Western Europe, this approval significantly increases patient access to minimally invasive valve replacement options.
Medtronic and Foxconn have partnered to manufacture 10,000 Puritan Bennett™ 560 ventilators in the U.S. over the next year, following Medtronic's ventilator open-source initiative. With Foxconn meeting Medtronic's regulatory standards, the production will take place in Mount Pleasant, Wisconsin. This collaboration aims to enhance ventilator supply critical for COVID-19 patients, with the possibility of doubling production if necessary. The PB560 model, introduced in 2010, is essential for managing severe respiratory illnesses.
Medtronic (NYSE: MDT) announced positive results from the ABRE clinical study, assessing the Abre venous self-expanding stent for iliofemoral outflow obstruction. The study demonstrated a 2.0% rate of major adverse events and an 88.0% primary patency rate at 12 months. Notable secondary endpoints included 100.0% device success and a 92.4% freedom from target lesion revascularization rate. Though Abre is currently investigational in the U.S., it received CE Mark approval in April 2017, indicating effective treatment options for patients with significant venous conditions.
Medtronic plc (NYSE: MDT) announced advancements in its extended wear infusion set technology during the American Diabetes Association's 80th Scientific Sessions. This new infusion set can be used safely for up to 7 days, more than twice the lifespan of current 3-day sets. Clinical studies indicate improved insulin stability, reducing the risk of hyperglycemia. Patients can potentially save 5-10 vials of insulin annually. The product has received the CE Mark, and a pivotal trial in the U.S. is underway to study its safety and efficacy.
Medtronic has announced a significant funding agreement with Blackstone Life Sciences to enhance its research and development in diabetes management. The collaboration will provide $337 million over several years, focusing on innovative insulin delivery and sensor technologies. This investment aims to address unmet needs for the 22 million global Type 1 diabetes patients. Medtronic plans to fast-track multiple development programs while the funding will cover R&D expenses, with potential royalties in the low- to mid-single digits if commercialized.
Medtronic announced positive results from two pivotal clinical trials for its MiniMed™ 780G automated insulin pump aimed at improving Type 1 diabetes management. The U.S. trial, focusing on ages 14-75, showed 96% user satisfaction, no severe hypoglycemia, and an average A1C of 7.0%. A New Zealand trial highlighted a 13-point boost in Time in Range for less-controlled patients. Bluetooth connectivity for real-time glucose monitoring is also a feature. The findings will support an upcoming FDA Premarket Approval application.
Medtronic (NYSE:MDT) has received CE Marking for its MiniMed™ 780G insulin pump, designed for type 1 diabetes patients aged 7 to 80. This system automates insulin delivery via the SmartGuard™ algorithm, providing basal insulin and correction boluses every five minutes. It allows customizable glucose targets and features Bluetooth connectivity for real-time glucose monitoring. Clinical feedback highlights improved diabetes management and quality of life. The MiniMed 780G is set to ship in select European markets this fall but is still under investigation in the U.S.
Medtronic (NYSE:MDT) announced participation in the American Diabetes Association's 80th Scientific Sessions, running from June 12-16, 2020. The company will present 16 data presentations, including a symposium on its Advanced Hybrid Closed-Loop Systems and related technologies. Medtronic's virtual exhibit will showcase innovations in diabetes technology and telehealth support. The presentation aims to highlight clinical outcomes and differentiated support offerings, focusing on improved diabetes management.